Moderna has dosed the first participants in its Phase 1/2 study of mRNA-1010, the company’s first quadrivalent seasonal influenza mRNA vaccine candidate to enter the clinic. The study will enroll 180 adult participants in the U.S. and targets WHO recommendations for the prevention of influenza, which causes respiratory illnesses and significant economic burdens on healthcare systems. Moderna plans to develop respiratory vaccines combining seasonal flu, COVID-19 variant booster, and RSV.
The first participants have been dosed in Moderna’s Phase 1/2 study of mRNA-1010, the Company’s first seasonal influenza vaccine candidate to enter the clinic, targeting WHO recommendations including A H1N1, H3N2, and influenza B Yamagata and Victoria. The randomized, stratified, observer-blind, dose-ranging study will assess the safety,
reactogenicity and immunogenicity of mRNA-1010 in healthy adults 18 years old and above in the U.S.
“Respiratory combination vaccines are an important pillar of our overall mRNA vaccine strategy. We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to rapidly respond to the evolution of respiratory viruses, such as influenza, SARS-CoV-2, and RSV. Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses. We look forward to advancing our core modality of prophylactic mRNA vaccines so that we can continue to make an impact on global public health,” commented Stéphane Bancel, Chief Executive Officer of Moderna.
According to the WHO, approximately 3-5 million people suffer from severe cases of flu globally each year, and 290,000-650,000 flu-related respiratory deaths occur. In the U.S., where an estimated 8% of the population experiences flu symptoms annually, the average economic burden of the illness is about $11 billion per year.
To address the limitations posed by current flu vaccines, Moderna is working to explore potential combination vaccines targeting flu, SARS-CoV-2, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV).
Moderna is an enterprise with a broad clinical portfolio of vaccines and therapeutics across six modalities, as well as an intellectual portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant for clinical and commercial production at scale and unprecedented speed. Moderna maintains relationships with a diverse range of collaborators and has most recently developed and had authorized one of the earliest and most effective vaccines against the COVID-19 pandemic.
Leveraging its mRNA platform, Moderna has 24 development programs underway across a range of therapeutic areas, with 15 having entered the clinic.
To learn more, visit www.modernatx.com.